Targeting the eIF4F translation initiation complex: A critical nexus for cancer development

Cancer Research

Volumn 75, Issue 2, 2015, Pages 250-263

  Pelletier, Jerry ^a,b   Graff, Jeremy ^c   Ruggero, Davide ^d   Sonenberg, Nahum ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c ELI LILLY AND COMPANY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DOCETAXEL; HIPPURISTANOL; INITIATION FACTOR 4A; INITIATION FACTOR 4E; INITIATION FACTOR 4F; INITIATION FACTOR 4G; LY 2275796; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PACLITAXEL; PREDNISONE; RAS PROTEIN; SILVESTROL; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SAFETY; EIF4E GENE; ENZYME PHOSPHORYLATION; EPITHELIAL MESENCHYMAL TRANSITION; FATIGUE; FEVER; GENE EXPRESSION REGULATION; GROWTH REGULATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NAUSEA; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NON SMALL CELL LUNG CANCER; NONHUMAN; PROTEIN ASSEMBLY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SECONDARY STRUCTURE; PROTEIN TARGETING; RIBOSOME; SIGNAL TRANSDUCTION; TRANSLATION INITIATION; UPREGULATION; VOMITING; ANIMAL; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; EUKARYOTIC INITIATION FACTOR-4F; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84920987074     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-2789     Document Type: Article

References (203)

1. Hershey JW, Sonenberg N, Mathews MB. Principles of translational control: an overview. Cold Spring Harb Perspect Biol 2012;4:pii: a011528.
2. Shatkin AJ. Capping of eucaryotic mRNAs. Cell 1976;9:645-53.
3. Horikami SM, De Ferra F, Moyer SA. Characterization of the infections of permissive and nonpermissive cells by host range mutants of vesicular stomatitis virus defective in RNA methylation. Virology 1984;138:1-15.
4. Pelletier J, Sonenberg N. Insertion mutagenesis to increase secondary structure within the 50 noncoding region of a eukaryotic mRNA reduces translational efficiency. Cell 1985;40:515-26.
5. Kozak M. In fluences of mRNA secondary structure on initiation by eukaryotic ribosomes. Proc Natl Acad Sci U S A 1986;83:2850-4.
6. ++-dependent cross-linking of cap binding proteins to the 50 end of eukaryotic mRNA. Nucleic Acids Res 1981;9: 1643-56.
7. Pelletier J, Sonenberg N. Photochemical cross-linking of cap binding proteins to eucaryotic mRNAs: effect of mRNA 50 secondary structure. Mol Cell Biol 1985;5:3222-30.
8. Kozak M. Influence of mRNA secondary structure on binding and migration of 40S ribosomal subunits. Cell 1980;19:79-90.
9. Morgan MA, Shatkin AJ. Initiation of reovirus transcription by inosine 5 0 -triphosphate and properties of 7-methylinosine-capped, ino-sine-substituted messenger ribonucleic acids. Biochemistry 1980;19: 5960-6.
10. Sonenberg N, Rupprecht KM, Hecht SM, Shatkin AJ. Eukaryotic mRNA cap binding protein: purification by affinity chromatography on sepharose-coupled m7GDP. Proc Natl Acad Sci U S A 1979;76: 4345-9.
11. Sonenberg N, Trachsel H, Hecht S, Shatkin AJ. Differential stimulation of capped mRNA translation in vitro by cap binding protein. Nature 1980;285:331-3.
12. Tahara SM, Morgan MA, Shatkin AJ. Two forms of puri fied m7G-cap binding protein with different effects on capped mRNA translation in extracts of uninfected and poliovirus-infected HeLa cells. J Biol Chem 1981;256:7691-4.
13. Duncan R, Hershey JW. Identification and quantitation of levels of protein synthesis initiation factors in crude HeLa cell lysates by twodimensional polyacrylamide gel electrophoresis. J Biol Chem 1983; 258:7228-35.
14. Galicia-Vazquez G, Cencic R, Robert F, Agenor AQ, Pelletier J. A cellular response linking eIF4AI activity to eIF4AII transcription. RNA 2012; 18:1373-84.
15. Conroy SC, Dever TE, Owens CL, Merrick WC. Characterization of the 46,000-dalton subunit of eIF-4F. Arch Biochem Biophys 1990;282: 363-71.
16. Yoder-Hill J, Pause A, Sonenberg N, Merrick WC. The p46 subunit of eukaryotic initiation factor (eIF)-4F exchanges with eIF-4A. J Biol Chem 1993;268:5566-73.
17. Nielsen PJ, McMaster GK, Trachsel H. Cloning of eukaryotic protein synthesis initiation factor genes: isolation and characterization of cDNA clones encoding factor eIF-4A. Nucleic Acids Res 1985;13: 6867-80.
18. Grifo JA, Tahara SM, Morgan MA, Shatkin AJ,Merrick WC. New initiation factor activity required for globin mRNA translation. J Biol Chem 1983;258:5804-10.
19. Edery I, Humbelin M, Darveau A, Lee KA, Milburn S, Hershey JW, et al. Involvement of eukaryotic initiation factor 4A in the cap recognition process. J Biol Chem 1983;258:11398-403.
20. Thomas A, Goumans H, Amesz H, Benne R, Voorma HO. A comparison of the initiation factors of eukaryotic protein synthesis from ribosomes and from the postribosomal supernatant. Eur J Biochem 1979;98:329-37.
21. Gradi A, Imataka H, Svitkin YV, Rom E, Raught B, Morino S, et al. A novel functional human eukaryotic translation initiation factor 4G. Mol Cell Biol 1998;18:334-42.
22. Kapp LD, Lorsch JR. The molecular mechanics of eukaryotic translation. Annu Rev Biochem 2004;73:657-704.
23. Imataka H, Sonenberg N. Human eukaryotic translation initiation factor 4G (eIF4G) possesses two separate and independent binding sites for eIF4A. Mol Cell Biol 1997;17:6940-7.
24. Rogers GW Jr, Richter NJ, Merrick WC. Biochemical and kinetic characterization of the RNA helicase activity of eukaryotic initiation factor 4A. J Biol Chem 1999;274:12236-44.
25. Chen Y, Potratz JP, Tijerina P, Del Campo M, Lambowitz AM, Russell R. DEAD-box proteins can completely separate an RNAduplex using a single ATP. Proc Natl Acad Sci U S A 2008;105:20203-8.
26. Ray BK, Lawson TG, Kramer JC, Cladaras MH, Grifo JA, Abramson RD, et al. ATP-dependent unwinding of messenger RNA structure by eukaryotic initiation factors. J Biol Chem 1985;260:7651-8.
27. Rogers GW Jr, Richter NJ, Lima WF, Merrick WC. Modulation of the helicase activity of eIF4A by eIF4B, eIF4H, and eIF4F. J Biol Chem 2001;276:30914-22.
28. Marintchev A, Edmonds KA, Marintcheva B, Hendrickson E, Oberer M, Suzuki C, et al. Topology and regulation of the human eIF4A/4G/4H helicase complex in translation initiation. Cell 2009;136: 447-60.
29. Rozovsky N, Butterworth AC, Moore MJ. Interactions between eIF4AI and its accessory factors eIF4B and eIF4H. RNA 2008;14:2136-48.
30. Bi X, Ren J, Goss DJ. Wheat germ translation initiation factor eIF4B affects eIF4A and eIFiso4F helicase activity by increasing the ATP binding affinity of eIF4A. Biochemistry 2000;39:5758-65.
31. Abramson RD, Dever TE, Merrick WC. Biochemical evidence supporting a mechanism for cap-independent and internal initiation of eukaryotic mRNA. J Biol Chem 1988;263:6016-9.
32. Dmitriev SE, Terenin IM, Dunaevsky YE, Merrick WC, Shatsky IN. Assembly of 48S translation initiation complexes from purified components with mRNAs that have some base pairing within their 50 untranslated regions. Mol Cell Biol 2003;23:8925-33.
33. Shahbazian D, Parsyan A, Petroulakis E, Topisirovic I, Martineau Y, Gibbs BF, et al. Control of cell survival and proliferation by mammalian eukaryotic initiation factor 4B. Mol Cell Biol 2010;30:1478-85.
34. Sarkar G, Edery I, Gallo R, Sonenberg N. Preferential stimulation of rabbit alpha globin mRNA translation by a cap-binding protein complex. Biochim Biophys Acta 1984;783:122-9.
35. Edery I, Lee KA, Sonenberg N. Functional characterization of eukaryotic mRNA cap binding protein complex: effects on translation of capped and naturally uncapped RNAs. Biochemistry 1984;23: 2456-62.
36. Pestova TV, Kolupaeva VG. The roles of individual eukaryotic translation initiation factors in ribosomal scanning and initiation codon selection. Genes Dev 2002;16:2906-22.
37. Svitkin YV, Pause A, Haghighat A, Pyronnet S, Witherell G, Belsham GJ, et al. The requirement for eukaryotic initiation factor 4A (elF4A) in translation is in direct proportion to the degree of mRNA 50 secondary structure. RNA 2001;7:382-94.
38. Marcotrigiano J, Gingras AC, Sonenberg N, Burley SK. Cocrystal structure of themessenger RNA 50 cap-binding protein (eIF4E) bound to 7-methyl-GDP. Cell 1997;89:951-61.
39. Tomoo K, Shen X, Okabe K, Nozoe Y, Fukuhara S, Morino S, et al. Crystal structures of 7-methylguanosine 5 0 -triphosphate (m(7)GTP)-and P(1)-7-methylguanosine-P(3)-adenosine-50, 5 0 -triphosphate (m(7) GpppA)-bound human full-length eukaryotic initiation factor 4E: biological importance of the C-terminal flexible region. Biochem J 2002;362: 539-44.
40. Matsuo H, Li H, McGuire AM, Fletcher CM, Gingras AC, Sonenberg N, et al. Structure of translation factor eIF4E bound to m7GDP and interaction with 4E-binding protein. Nat Struct Biol 1997;4:717-24.
41. Berset C, Zurbriggen A, Djafarzadeh S, Altmann M, Trachsel H. RNAbinding activity of translation initiation factor eIF4G1 from Saccharomyces cerevisiae. Rna 2003;9:871-80.
42. Yanagiya A, Svitkin YV, Shibata S, Mikami S, Imataka H, Sonenberg N. Requirement of RNA binding of mammalian eukaryotic translation initiation factor 4GI (eIF4GI) for ef ficient interaction of eIF4E with the mRNA cap. Mol Cell Biol 2009;29:1661-9.
43. Haghighat A, Sonenberg N. eIF4G dramatically enhances the binding of eIF4E to the mRNA 50 -cap structure. J Biol Chem 1997;272:21677-80.
44. Godefroy-Colburn T, Ravelonandro M, Pinck L. Cap accessibility correlates with the initiation efficiency of alfalfa mosaic virus RNAs. Eur J Biochem 1985;147:549-52.
45. Lawson TG, Cladaras MH, Ray BK, Lee KA, Abramson RD, Merrick WC, et al. Discriminatory interaction of purified eukaryotic initiation factors 4F plus 4A with the 50 ends of reovirus messenger RNAs. J Biol Chem 1988;263:7266-76.
46. Parkin NT, Cohen EA, Darveau A, Rosen C, Haseltine W, Sonenberg N. Mutational analysis of the 50 non-coding region of human immunodeficiency virus type 1: effects of secondary structure on translation. EMBO J 1988;7:2831-7.
47. Svitkin YV, Evdokimova VM, Brasey A, Pestova TV, Fantus D, Yanagiya A, et al. General RNA-binding proteins have a function in poly(A)-binding protein-dependent translation. EMBO J 2009;28:58-68.
48. Svitkin YV, Ovchinnikov LP, Dreyfuss G, Sonenberg N. General RNA binding proteins render translation cap dependent. Embo J 1996;15: 7147-55.
49. Lawson TG, Ray BK, Dodds JT, Grifo JA, Abramson RD, Merrick WC, et al. Influence of 50 proximal secondary structure on the translational efficiency of eukaryotic mRNAs and on their interaction with initiation factors. J Biol Chem 1986;261:13979-89.
50. Rogers GW Jr, Lima WF, Merrick WC. Further characterization of the helicase activity of eIF4A. Substrate specificity. J Biol Chem 2001;276: 12598-608.
51. Rozen F, Edery I, Meerovitch K, Dever TE, Merrick WC, Sonenberg N. Bidirectional RNA helicase activity of eucaryotic translation initiation factors 4A and 4F. Mol Cell Biol 1990;10:1134-44.
52. Pause A, Sonenberg N. Mutational analysis of a DEAD box RNA helicase: the mammalian translation initiation factor eIF-4A. EMBO J 1992;11: 2643-54.
53. Feoktistova K, Tuvshintogs E, Do A, Fraser CS. Human eIF4E promotes mRNA restructuring by stimulating eIF4A helicase activity. Proc Natl Acad Sci U S A 2013;110:13339-44.
54. Duncan R, Milburn SC, Hershey JW. Regulated phosphorylation and low abundance of HeLa cell initiation factor eIF-4F suggest a role in translational control. Heat shock effects on eIF-4F. J Biol Chem 1987;262:380-8.
55. Sonenberg N. Cap-binding proteins of eukaryotic messenger RNA: functions in initiation and control of translation. Prog Nucleic Acid Res Mol Biol 1988;35:173-207.
56. Lindqvist L, Imataka H, Pelletier J. Cap-dependent eukaryotic initiation factor-mRNA interactions probed by cross-linking. RNA 2008;14:960-9.
57. Tarun SZ Jr, Sachs AB. Association of the yeast poly(A) tail binding protein with translation initiation factor eIF-4G. Embo J 1996;15:7168-77.
58. Tarun SZ Jr, Sachs AB. A common function for mRNA 50 and 30 ends in translation initiation in yeast. Genes Dev 1995;9:2997-3007.
59. Kahvejian A, Svitkin YV, Sukarieh R, M'Boutchou M-N, Sonenberg N. Mammalian poly(A)-binding protien is a eukaryotic translation initiation factor, which acts via multiplemechanisms. Genes Dev 2005;19:104-13.
60. Luo Y, Goss DJ. Homeostasis in mRNA initiation: wheat germ poly(A)-binding protein lowers the activation energy barrier to initiation complex formation. J Biol Chem 2001;276:43083-6.
61. Borman AM, Michel YM, Kean KM. Biochemical characterisation of cappoly (A) synergy in rabbit reticulocyte lysates: the eIF4G-PABP interaction increases the functional affinity of eIF4E for the capped mRNA 50 -end. Nucleic Acids Res 2000;28:4068-75.
62. Borman AM, Michel YM, Malnou CE, Kean KM. Free poly(A) stimulates capped mRNA translation in vitro through the eIF4G-poly(A)-binding protein interaction. J Biol Chem 2002;277:36818-24.
63. Bi X, Goss DJ. Wheat germ poly(A)-binding protein increases the ATPase and the RNA helicase activity of translation initiation factors eIF4A, eIF4B, and eIF-iso4F. J Biol Chem 2000;275:17740-6.
64. Park EH, Walker SE, Lee JM, Rothenburg S, Lorsch JR, Hinnebusch AG. Multiple elements in the eIF4G1 N-terminus promote assembly of eIF4G1- PABP mRNPs in vivo. EMBO J 2011;30:302-16.
65. Asselbergs FA, Peters W, Venrooij WJ, Bloemendal H. Diminished sensitivity of re-initiation of translation to inhibition by cap analogues in reticulocyte lysates. Eur J Biochem 1978;88:483-8.
66. Park EH, Zhang F, Warringer J, Sunnerhagen P, Hinnebusch AG. Depletion of eIF4G from yeast cells narrows the range of translational efficiencies genome-wide. BMC Genomics 2011;12:68.
67. Wakiyama M, Imataka H, Sonenberg N. Interaction of eIF4G with poly (A)-binding protein stimulates translation and is critical for Xenopus oocyte maturation. Curr Biol 2000;10:1147-50.
68. Shantz LM, Pegg AE. Overproduction of ornithine decarboxylase caused by relief of translational repression is associated with neoplastic transformation. Cancer Res 1994;54:2313-6.
69. De Benedetti A, Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene 2004;23:3189-99.
70. Silvera D, Formenti SC, Schneider RJ. Translational control in cancer. Nat Rev Cancer 2010;10:254-66.
71. Grolleau A, Bowman J, Pradet-Balade B, Puravs E, Hanash S, Garcia-Sanz JA, et al. Global and specifi c translational control by rapamycin in T cells uncovered by microarrays and proteomics. J Biol Chem 2002;277: 22175-84.
72. Mamane Y, Petroulakis E, Martineau Y, Sato TA, LarssonO, Rajasekhar VK, et al. Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation. PLoS ONE 2007;2:e242.
73. Tcherkezian J, Cargnello M, Romeo Y, Huttlin EL, Lavoie G, Gygi SP, et al. Proteomic analysis of cap-dependent translation identi fies LARP1 as a key regulator of 50 TOP mRNA translation. Genes Dev 2014;28: 357-71.
74. Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 2012;485:55-61.
75. Thoreen CC, Chantranupong L, Keys HR, Wang T, Gray NS, Sabatini DM. A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 2012;485:109-13.
76. Cunningham JT, Moreno MV, Lodi A, Rosen SM, Ruggero D Protein and nucleotide biosynthesis are coupled by a single rate-limiting enzyme. PRPS2, to drive cancer. Cell 2014;157:1088-103.
77. Morita M, Gravel SP, Chenard V, Sikstrom K, Zheng L, Alain T, et al. mTORC1 controls mitochondrial activity and biogenesis through 4E-BPdependent translational regulation. Cell Metab 2013;18:698-711.
78. Piccirillo CA, Bjur E, Topisirovic I, Sonenberg N, Larsson O. Translational control of immune responses: from transcripts to translatomes. Nat Immunol 2014;15:503-11.
79. Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T, et al. Dissecting eIF4E action in tumorigenesis. Genes Dev 2007;21:3232-7.
80. Furic L, Rong L, Larsson O, Koumakpayi IH, Yoshida K, Brueschke A, et al. eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci U S A 2010; 107:14134-9.
81. Robichaud N, Del Rincon SV, Huor B, Alain T, Petruccelli LA, Hearnden J, et al. Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3. Oncogene 2014. Jun 9. doi: 10.1038/onc.2014.146. [Epub ahead of print].
82. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. Semin Cancer Biol 2006;16:253-64.
83. Barrans S, Crouch S, Smith A, Turner K, Owen R, Patmore R, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 2010;28:3360-5.
84. Wolfer A, Wittner BS, Irimia D, Flavin RJ, Lupien M, Gunawardane RN, et al. MYC regulation of a "poor-prognosis" metastatic cancer cell state. Proc Natl Acad Sci U S A 2010;107:3698-703.
85. Barna M, Pusic A, Zollo O, Costa M, Kondrashov N, Rego E, et al. Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. Nature 2008;456:971-5.
86. Rosenwald IB, Rhoads DB, Callanan LD, et al. Increased expression of eukaryotic translation initiation factors eIF-4E and eIF-2 a in response to growth induction by c-myc. Proc Natl Acad Sci U S A 1993;90:6175-8.
87. Jones RM, Branda J, Johnston KA, et al. An essential E box in the promoter of the gene encoding the mRNA cap-binding protein (eukaryotic initiation factor 4E) is a target for activation by c-myc. Mol Cell Biol 1996;16:4754-64.
88. Lin CJ, Cencic R, Mills JR, Robert F, Pelletier J. c-Myc and eIF4F are components of a feedforward loop that links transcription and translation. Cancer Res 2008;68:5326-34.
89. Lin CJ, Nasr Z, Premsrirut PK, Porco JA Jr, Hippo Y, Lowe SW, et al. Targeting synthetic lethal interactions between Myc and the eIF4F complex impedes tumorigenesis. Cell Reports 2012;1:325-33.
90. Polunovsky VA, Rosenwald IB, Tan AT, White J, Chiang L, Sonenberg N, et al. Translational control of programmed cell death: eukaryotic translation initiation factor 4E blocks apoptosis in growth-factor-restricted fibroblasts with physiologically expressed or deregulated Myc. Mol Cell Biol 1996;16:6573-81.
91. Tan A, Bitterman P, Sonenberg N, Peterson M, Polunovsky V. Inhibition of Myc-dependent apoptosis by eukaryotic translation initiation factor 4E requires cyclin D1. Oncogene 2000;19:1437-47.
92. Pourdehnad M, Truitt ML, Siddiqi IN, Ducker GS, Shokat KM, Ruggero D. Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Proc Natl Acad Sci U S A 2013;110:11988-93.
93. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22.
94. Gingras AC, Raught B, Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 1999;68:913-63.
95. Yang HS, Jansen AP, Komar AA, Zheng X, Merrick WC, Costes S, et al. The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol Cell Biol 2003;23:26-37.
96. Suzuki C, Garces RG, Edmonds KA, Hiller S, Hyberts SG, Marintchev A, et al. PDCD4 inhibits translation initiation by binding to eIF4A using both its MA3 domains. Proc Natl Acad Sci U S A 2008;105:3274-9.
97. Dorrello NV, Peschiaroli A, Guardavaccaro D, Colburn NH, Sherman NE, Pagano M. S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 2006;314: 467-71.
98. Shahbazian D, Roux PP, Mieulet V, Cohen MS, Raught B, Taunton J, et al. The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. Embo J 2006;25:2781-91.
99. Holz MK, Ballif BA, Gygi SP, Blenis J. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 2005; 123:569-80.
100. Kroczynska B, Kaur S, Katsoulidis E,Majchrzak-Kita B, Sassano A, Kozma SC, et al. Interferon-dependent engagement of eukaryotic initiation factor 4B via S6 kinase (S6K)- and ribosomal protein S6K-mediated signals. Mol Cell Biol 2009;29:2865-75.
101. van Gorp AG, van der Vos KE, Brenkman AB, Bremer A, van den Broek N, Zwartkruis F, et al. AGC kinases regulate phosphorylation and activation of eukaryotic translation initiation factor 4B. Oncogene 2009;28:95-106.
102. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005;121:179-93.
103. Rinker-Schaeffer CW, Austin V, Zimmer S, Rhoads RE. Ras transformation of cloned rat embryo fibroblasts results in increased rates of protein synthesis and phosphorylation of eukaryotic initiation factor 4E. J Biol Chem 1992;267:10659-64.
104. Flynn A, Proud CG. Serine 209, not serine 53, is the major site of phosphorylation in initiation factor eIF-4E in serum-treated Chinese hamster ovary cells. J Biol Chem 1995;270:21684-8.
105. Joshi B, Cai AL, Keiper BD, Minich WB, Mendez R, Beach CM, et al. Phosphorylation of eukaryotic protein synthesis initiation factor 4E at Ser-209. J Biol Chem 1995;270:14597-603.
106. Waskiewicz AJ, Johnson JC, Penn B,Mahalingam M, Kimball SR, Cooper JA. Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo. Mol Cell Biol 1999;19:1871-80.
107. Pyronnet S, Imataka H, Gingras AC, Fukunaga R, Hunter T, Sonenberg N. Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E. EMBO J 1999;18:270-9.
108. Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata S, Fukunaga R. Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol Cell Biol 2004;24:6539-49.
109. Scheper GC, van Kollenburg B, Hu J, Luo Y, Goss DJ, Proud CG. Phosphorylation of eukaryotic initiation factor 4E markedly reduces its affinity for capped mRNA. J Biol Chem 2002;277:3303-9.
110. Slepenkov SV, Darzynkiewicz E, Rhoads RE. Stopped-flow kinetic analysis of eIF4E and phosphorylated eIF4E binding to cap analogs and capped oligoribonucleotides: evidence for a one-step binding mechanism. J Biol Chem 2006;281:14927-38.
111. Zuberek J, Jemielity J, Jablonowska A, Stepinski J, Dadlez M, Stolarski R, et al. Influence of electric charge variation at residues 209 and 159 on the interaction of eIF4E with the mRNA 50 terminus. Biochemistry 2004; 43:5370-9.
112. Zuberek J,Wyslouch-Cieszynska A, Niedzwiecka A,Dadlez M, Stepinski J, Augustyniak W, et al. Phosphorylation of eIF4E attenuates its interaction with mRNA 50 cap analogs by electrostatic repulsion: intein-mediated protein ligation strategy to obtain phosphorylated protein. RNA 2003; 9:52-61.
113. Scheper GC, Proud CG. Does phosphorylation of the cap-binding protein eIF4E play a role in translation initiation? Eur J Biochem 2002;269: 5350-9.
114. Topisirovic I, Ruiz-Gutierrez M, Borden KL. Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities. Cancer Res 2004;64: 8639-42.
115. Lazaris-Karatzas A, Montine KS, Sonenberg N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 50 cap. Nature 1990;345:544-7.
116. Rinker-Schaeffer CW, Graff JR, DeBenedetti A, Zimmer SG, Rhoads RE. Decreasing the level of translation initiation factor 4E with antisense RNA causes reversal of ras-mediated transformation and tumorigenesis of cloned rat embryo fibroblasts. Int J Cancer 1993;55:841-7.
117. Ruggero D, Montanaro L, Ma L, Xu W, Londei P, Cordon-Cardo C, et al. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 2004;10:484-6.
118. Wendel H-G, de Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004;428:332-7.
119. Ueda T, Sasaki M, Elia AJ, Chio II, Hamada K, Fukunaga R, et al. Combined deficiency forMAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development. Proc Natl Acad Sci U S A 2010;107:13984-90.
120. Konicek BW, Stephens JR, McNulty AM, Robichaud N, Peery RB, Dumstorf CA, et al. Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases. Cancer Res 2011;71:1849-57.
121. Rajasekhar VK, Viale A, Socci ND, Wiedmann M, Hu X, Holland EC. Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol Cell 2003;12:889-901.
122. Avdulov S, Li S,Michalek V, Burrichter D, PetersonM, Perlman DM, et al. Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 2004;5:553-63.
123. Nasr Z, Robert F, Porco JA Jr., Muller WJ, Pelletier J. eIF4F suppression in breast cancer affects maintenance and progression. Oncogene 2013;32: 861-71.
124. Rosenwald IB, Lazaris-Karatzas A, Sonenberg N, Schmidt EV. Elevated levels of cyclin D1 protein in response to increased expression of eukaryotic initiation factor 4E. Mol Cell Biol 1993;13:7358-63.
125. Rousseau D, Kaspar R, Rosenwald I, Gehrke L, Sonenberg N. Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E. Proc Natl Acad Sci U S A 1996;93:1065-70.
126. Shantz LM, Coleman CS, Pegg AE. Expression of an ornithine decarboxylase dominant-negative mutant reverses eukaryotic initiation factor 4Einduced cell transformation. Cancer Res 1996;56:5136-40.
127. Graff JR, Konicek BW, Carter JH, Marcusson EG. Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res 2008; 68:631-4.
128. Graff JR, Boghaert ER, De Benedetti A, Tudor DL, Zimmer CC, Chan SK, et al. Reduction of translation initiation factor 4E decreases the malignancy of ras-transformed cloned rat embryo fibroblasts. Int J Cancer 1995;60:255-63.
129. Graff JR, Konicek BW, Vincent TM, Lynch RL, Monteith D, Weir SN, et al. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest 2007;117:2638-48.
130. Graff JR, Zimmer SG. Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin Exp Met 2003;20:265-73.
131. Nasr Z, Pelletier J. Tumor progression and metastasis: role of translational deregulation. Anticancer Res 2012;32:3077-84.
132. Zimmer SG, DeBenedetti A, Graff JR. Translational control of malignancy: the mRNA cap-binding protein, eIF4E, as a central regulator of tumor formation, growth, invasion and metastasis. Anticancer Res 2000; 20:1343-1351.
133. Kevil CG, De Benedetti A, Payne DK, Coe LL, Laroux FS, Alexander JS. Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: implications for tumor angiogenesis. Int J Cancer 1996;65:785-90.
134. Kevil C, Carter P, Hu B, DeBenedetti A. Translational enhancement of FGF-2 by eIF-4 factors, and alternate utilization of CUG and AUG codons for translation initiation. Oncogene 1995;11:2339-48.
135. Zhou S, Wang GP, Liu C, ZhouM. Eukaryotic initiation factor 4E (eIF4E) and angiogenesis: prognostic markers for breast cancer. BMC Cancer 2006;6:231.
136. Nathan CA, Franklin S, Abreo FW, Nassar R, de Benedetti A, Williams J, et al. Expression of eIF4E during head and neck tumorigenesis: possible role in angiogenesis. Laryngoscope 1999;109:1253-8.
137. Cencic R, Carrier M, Galicia-Vazquez G, Bordeleau ME, Sukarieh R, Bourdeau A, et al. Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol. PLoS ONE 2009;4:e5223.
138. Li S, Takasu T, Perlman DM, Peterson MS, Burrichter D, Avdulov S, et al. Translation factor eIF4E rescues cells from Myc-dependent apoptosis by inhibiting cytochrome c release. J Biol Chem 2003;278: 3015-22.
139. Larsson O, Perlman DM, Fan D, Reilly CS, Peterson M, Dahlgren C, et al. Apoptosis resistance downstream of eIF4E: posttranscriptional activation of an anti-apoptotic transcript carrying a consensus hairpin structure. Nucleic Acids Res 2006;34:4375-86.
140. Wai PY, Kuo PC. Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 2008;27:103-18.
141. Graff JR, Konicek BW, Lynch RL, Dumstorf CA, Dowless MS,McNulty AM, et al. eIF4E activation is commonly elevated in advanced human prostate cancers and signi ficantly related to reduced patient survival. Cancer Res 2009;69:3866-73.
142. Pardo OE, Arcaro A, Salerno G, Raguz S, Downward J, Seckl MJ. Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway: correlation with resistance to etoposideinduced apoptosis. J Biol Chem 2002;277:12040-6.
143. Jiang Y, Muschel RJ. Regulation of matrix metalloproteinase-9 (MMP-9) by translational efficiency in murine prostate carcinoma cells. Cancer Res 2002;62:1910-4.
144. Yang YJ, Zhang YL, Li X, Dan HL, Lai ZS, Wang JD, et al. Contribution of eIF-4E inhibition to the expression and activity of heparanase in human colon adenocarcinoma cell line: LS-174T. World J Gastroenterol 2003;9:1707-12.
145. Evdokimova V, Tognon C, Ng T, Ruzanov P, Melnyk N, Fink D, et al. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell 2009;15:402-15.
146. Haydon MS, Googe JD, Sorrells DS, Ghali GE, Li BD. Progression of eIF4e gene amplification and overexpression in benign and malignant tumors of the head and neck. Cancer 2000;88:2803-10.
147. Rosenwald IB, Chen JJ, Wang S, Savas L, London IM, Pullman J. Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis. Oncogene 1999;18:2507-17.
148. Armengol G, Rojo F,Castellvi J, Iglesias C, Cuatrecasas M, Pons B, et al. 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. Cancer Res 2007;67:7551-5.
149. Wendel HG, Malina A, Zhao Z, Zender L, Kogan SC, Cordon-Cardo C, et al. Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res 2006;66:7639-46.
150. Ilic N, Utermark T, Widlund HR, Roberts TM. PI3K-targeted therapy can be evaded by gene ampli fication along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc Natl Acad Sci U S A 2011;108: E699-708.
151. Cope CL, Gilley R, Balmanno K, Sale MJ, Howarth KD, Hampson M, et al. Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation. J Cell Sci 2014;127: 788-800.
152. Boussemart L, Malka-Mahieu H, Girault I, Allard D, Hemmingsson O, Tomasic G, et al. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. Nature 2014;513:105-9.
153. Croft A, Tay KH, Boyd SC, Guo ST, Jiang CC, Lai F, et al. Oncogenic activation of MEK/ERK primes melanoma cells for adaptation to endoplasmic reticulum stress. J Invest Dermatol 2014;134: 488-97.
154. Robert F, Roman W, Bramoulle A, Fellmann C, Roulston A, Shustik C, et al. Translation initiation factor eIF4F modifies the dexamethasone response in multiple myeloma. Proc Natl Acad Sci U S A 2014;111: 13421-6.
155. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010;463:899-905.
156. Hill JM, Roberts J, Loeb E, Khan A, MacLellan A, Hill RW. L-asparaginase therapy for leukemia and other malignant neoplasms. Remission in human leukemia. JAMA 1967;202:882-8.
157. O'Brien S, Kantarjian H, Keating M, Beran M, Koller C, Robertson LE, et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 1995; 86:3322-6.
158. Malina A, Mills JR, Pelletier J. Emerging therapeutics targeting mRNA translation. Cold Spring Harbor Perspect Biol 2012;4:a012377.
159. Hsieh AC, Costa M, Zollo O, Davis C, Feldman ME, Testa JR. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 2010;17: 249-61.
160. Li S, Sonenberg N, Gingras AC, Peterson M, Avdulov S, Polunovsky VA, et al. Translational control of cell fate: availability of phosphorylation sites on translational repressor 4E-BP1 governs its proapoptotic potency. Mol Cell Biol 2002;22:2853-61.
161. Herbert TP, Fahraeus R, Prescott A, Lane DP, Proud CG. Rapid induction of apoptosis mediated by peptides that bind initiation factor eIF4E. Curr Biol 2000;10:793-6.
162. Brown CJ, Lim JJ, Leonard T, Lim HC, Chia CS, Verma CS, et al. Stabilizing the eIF4G1 alpha-helix increases its binding affinity with eIF4E: implications for peptidomimetic design strategies. J Mol Biol 2011;405:736-53.
163. Jemielity J, Kowalska J, Rydzik AM, Darzynkiewicz E. SyntheticmRNAcap analogs with a modified triphosphate bridge-synthesis, applications and prospects. N J Chem 2010:829-44.
164. Wagner CR, Iyer VV, McIntee EJ. Pronucleotides: toward the in vivo delivery of antiviral and anticancer nucleotides. Med Res Rev 2000;20: 417-51.
165. Kentsis A, Topisirovic I, Culjkovic B, Shao L, Borden KL. Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap. Proc Natl Acad Sci U S A 2004; 101:18105-10.
166. Yan Y, Svitkin Y, Lee JM, Bisaillon M, Pelletier J. Ribavirin is not a functional mimic of the 7-methyl guanosine mRNA cap. RNA 2005;11: 1238-44.
167. Westman B, Beeren L, Grudzien E, Stepinski J, Worch R, Zuberek J, et al. The antiviral drug ribavirin does not mimic the 7-methylguanosine moiety of the mRNA cap structure in vitro. RNA 2005;11:1505-13.
168. Ghosh B, Benyumov AO, Ghosh P, Jia Y, Avdulov S, Dahlberg PS, et al. Nontoxic chemical interdiction of the epithelial-to-mesenchymal transition by targeting cap-dependent translation. ACS Chem Biol 2009;4: 367-77.
169. Li S, Jia Y, Jacobson B, McCauley J, Kratzke R, Bitterman PB, et al. Treatment of breast and lung cancer cells with a N-7 benzyl guanosine monophosphate tryptamine phosphoramidate pronucleotide (4Ei-1) results in chemosensitization to gemcitabine and induced eIF4E proteasomal degradation. Mol Pharm 2013;10: 523-31.
170. Chen EZ, Jacobson BA, Patel MR, Okon AM, Li S, Xiong K, et al. Smallmolecule inhibition of oncogenic eukaryotic protein translation in mesothelioma cells. Investigational new drugs 2014;32:598-603.
171. Moerke NJ, Aktas H, Chen H, Cantel S, Reibarkh MY, Fahmy A, et al. Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell 2007;128:257-67.
172. Cencic R, Hall DR, Robert F, Du Y, Min J, Li L, et al. Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F. Proc Natl Acad Sci U S A 2011;108:1046-51.
173. Hong DS, Kurzrock R,Oh Y, Wheler J, Naing A, Brail L, et al. Aphase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res 2011;17:6582-91.
174. Bordeleau ME, Matthews J, Wojnar JM, Lindqvist L, Novac O, Jankowsky E, et al. Stimulation of mammalian translation initiation factor eIF4A activity by a small molecule inhibitor of eukaryotic translation. Proc Natl Acad Sci U S A 2005;102:10460-5.
175. Bordeleau M-E, Mori A, Oberer M, Lindqvist L, Chard LS, Higa T, et al. Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A. Nat Chem Biol 2006;2:213-20.
176. Bordeleau ME, Robert F, Gerard B, Lindqvist L, Chen SM, Wendel HG, et al. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J Clin Invest 2008;118: 2651-60.
177. Sun Y, Atas E, Lindqvist LM, Sonenberg N, Pelletier J, Meller A. Singlemolecule kinetics of the eukaryotic initiation factor 4AI upon RNA unwinding. Structure 2014;22:941-8.
178. Bordeleau ME, Cencic R, Lindqvist L, Oberer M, Northcote P, Wagner G, et al. RNA-mediated sequestration of the RNA helicase eIF4A by pateamine A inhibits translation initiation. Chem Biol 2006;13: 1287-95.
179. Tsumuraya T, Ishikawa C, Machijima Y, Nakachi S, Senba M, Tanaka J, et al. Effects of hippuristanol, an inhibitor of eIF4A, on adult T-cell leukemia. Biochem Pharmacol 2011;81:713-22.
180. Kuznetsov G, Xu Q, Rudolph-Owen L, Tendyke K, Liu J, Towle M, et al. Potent in vitro and in vivo anticancer activities of des-methyl, des-amino pateamine A, a synthetic analogue of marine natural product pateamine A. Mol Cancer Ther 2009;8:1250-60.
181. Kogure T, Kinghorn AD, Yan I, Bolon B, Lucas DM, Grever MR, et al. Therapeutic potential of the translation inhibitor silvestrol in hepatocellular cancer. PLoS ONE 2013;8:e76136.
182. Lucas DM, Edwards RB, Lozanski G, West DA, Shin JD, Vargo MA, et al. The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood 2009;113:4656-66.
183. Cencic R, Robert F, Galicia-Vazquez G, Malina A, Ravindar K, Somaiah R, et al. Modifying chemotherapy response by targeted inhibition of eukaryotic initiation factor 4A. Blood Cancer J 2013;3: e128.
184. Saradhi UV, Gupta SV, Chiu M, Wang J, Ling Y, Liu Z, et al. Characterization of silvestrol pharmacokinetics in mice using liquid chromatography-tandem mass spectrometry. AAPS J 2011;13: 347-56.
185. Sadlish H, Galicia-Vazquez G, Paris CG, Aust T, Bhullar B, Chang L, et al. Evidence for a functionally relevant rocaglamide binding site on the eIF4A-RNA complex. ACS Chem Biol 2013;8:1519-27.
186. Liu T, Nair SJ, Lescarbeau A, Belani J, Peluso S, Conley J, et al. Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors. J Med Chem 2012;55:8859-78.
187. Wolfe AL, Singh K, Zhong Y, Drewe P, Rajasekhar VK, Sanghvi VR, et al. RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer. Nature 2014;513:65-70.
188. Rubio CA, Weisburd B, Holderfield M, Arias C, Fang E, DeRisi JL, et al. Transcriptome-wide characterization of the eIF4A signature highlights plasticity in translation regulation. Genome Biol 2014;15: 476.
189. Gupta SV, Sass EJ, Davis ME, Edwards RB, Lozanski G, Heerema NA, et al. Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cells. AAPS J 2011;13:357-64.
190. Tschopp C, Knauf U, Brauchle M, Zurini M, Ramage P, Glueck D, et al. Phosphorylation of eIF-4E on Ser 209 in response to mitogenic and inflammatory stimuli is faithfully detected by specific antibodies. Mol Cell Biol Res Commun 2000;3:205-11.
191. Knauf U, Tschopp C, Gram H. Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2. Mol Cell Biol 2001;21:5500-11.
192. Diab S, Teo T, Kumarasiri M, Li P, Yu M, Lam F, et al. Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation. ChemMedChem 2014;9:962-72.
193. Altman JK, Szilard A, Konicek BW, Iversen PW, Kroczynska B, Glaser H, et al. Inhibition ofMnkkinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors. Blood 2013;121:3675-81.
194. Alain T, Morita M, Fonseca BD, Yanagiya A, Siddiqui N, Bhat M, et al. eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies. Cancer Res 2012;72:6468-76.
195. Fukuchi-Shimogori T, Ishii I, Kashiwagi K, Mashiba H, Ekimoto H, Igarashi K. Malignant transformation by overproduction of translation initiation factor eIF4G. Cancer Res 1997;57:5041-4.
196. Ramirez-Valle F, Braunstein S, Zavadil J, Formenti SC, Schneider RJ. eIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy. J Cell Biol 2008;181:293-307.
197. Hayashi S, Nishimura K, Fukuchi-Shimogori T, Kashiwagi K, Igarashi K. Increase in cap- and IRES-dependent protein synthesis by overproduction of translation initiation factor eIF4G. Biochem Biophys Res Commun 2000;277:117-23.
198. Silvera D, Arju R, Darvishian F, Levine PH, Zolfaghari L, Goldberg J, et al. Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer. Nat Cell Biol 2009;11:903-8.
199. Elfakess R, Dikstein R. A translation initiation element specific to mRNAs with very short 50 UTR that also regulates transcription. PLoS ONE 2008;3:e3094.
200. Elfakess R, Sinvani H, Haimov O, Svitkin Y, Sonenberg N, Dikstein R. Unique translation initiation of mRNAs-containing TISU element. Nucleic Acids Res 2011;39:7598-609.
201. Hann SR, Eisenman RN. Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells. Mol Cell Biol 1984;4:2486-97.
202. Muise-Helmericks RC, Grimes HL, Bellacosa A, Malstrom SE, Tsichlis PN, Rosen N. Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem 1998;273:29864-72.
203. Ramon YCS, De Mattos-Arruda L, Sonenberg N, Cortes J, Peg V. The intratumor heterogeneity of cell signaling factors in breast cancer: p4E-BP1 and peIF4E are diffusely expressed and are real potential targets. Clin Transl Oncol 2014;16:937-41.